Rabbit Polyclonal CACNA1H Antibody

CACNA1H antibodies target the α1H subunit of voltage-gated calcium channels (CaV3.2), a T-type channel primarily involved in low-threshold calcium currents. These channels regulate cellular excitability in neurons, cardiac cells, and endocrine tissues. CACNA1H gene mutations are linked to neurological disorders (e.g., childhood absence epilepsy, autism spectrum disorders) and endocrine conditions like primary aldosteronism. Antibodies against CACNA1H are research tools used to study channel expression, localization, and dysfunction in disease models. In autoimmune contexts, anti-CACNA1H autoantibodies have been reported in some cases of autoimmune encephalitis or cerebellar ataxia, though their pathogenic role remains less defined compared to antibodies targeting other calcium channel subtypes (e.g., CaV2.1 in Lambert-Eaton syndrome). Commercially available antibodies are typically validated for techniques like Western blotting, immunohistochemistry, or immunofluorescence in human, rodent, or primate tissues. Research focuses on clarifying CACNA1H's role in synaptic plasticity, hormone secretion, and arrhythmias, as well as exploring therapeutic modulation of T-type channels. Challenges include the channel's complex post-translational modifications and splice variants, which may affect antibody specificity. Proper validation using knockout controls is critical for experimental accuracy.